Descrição

Psychiatric disorder outcomes including depression and anxiety from EPA-predominant versus DHA-predominant supplement trials are compared.

Figure 25

Source Paper

Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete against Each Other?

Nutrients (2020)

PMID: 33276463

DOI: 10.3390/nu12123718

Cite This Figure

![Figure 25: Psychiatric disorder outcomes including depression and anxiety from EPA-predominant versus DHA-predominant supplement trials are compared.]()

> Source: Anandita Pal et al. "Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete ." *Nutrients*, 2020. PMID: [33276463](https://pubmed.ncbi.nlm.nih.gov/33276463/)

<figure>
  <img src="" alt="Psychiatric disorder outcomes including depression and anxiety from EPA-predominant versus DHA-predominant supplement trials are compared." />
  <figcaption>Figure 25. Psychiatric disorder outcomes including depression and anxiety from EPA-predominant versus DHA-predominant supplement trials are compared.<br>  Source: Anandita Pal et al. "Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete ." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33276463/">33276463</a></figcaption>
</figure>

Evidências Relacionadas

Omega-3 Fatty Acids (EPA/DHA) para Chronic Inflammation

Nota A · 30 estudos